Varian Medical Systems Bolsters Oncology Unit With Zmed Purchase
This article was originally published in The Gray Sheet
Executive Summary
Varian Medical System's acquisition of SonArray three-dimensional ultrasound technology will enable the firm to enhance its image-guided radiotherapy line for radiation oncology clinics
You may also be interested in...
Lehman Brothers Global Healthcare Conference In Brief
Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...
Lehman Brothers Global Healthcare Conference In Brief
Gen-Probe pursues HPV assay: Human papillomavirus test technology access is being sought by the company, which has held discussions with "three or four" developers thus far about potential "ways to collaborate," CFO Herm Rosenman reported March 3 at the Lehman Brothers Global Healthcare Conference in South Beach, Florida. HPV market participants include Digene (DNAwithPap) and Roche (Amplicor). Should discussions be unsuccessful, Gen-Probe "will continue to engineer our own" intellectual property to work around current barriers to entering the market, according to Rosenman. Gen-Probe projects $235 mil.-$245 mil. in revenue this year, supported by strong sales of its Tigris automated nucleic acid test platform (1"The Gray Sheet" Jan. 5, 2004, p. 5)...
Nomos Goes Public Via North American Scientific Merger Valued At $56 Mil.
Radiation oncology firm North American Scientific, Inc. (NASI) will more than triple its revenue to $55-$60 mil. with the purchase of intensity modulated radiation therapy (IMRT) developer Nomos under an Oct. 27 agreement